2021

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49 Neoplasms
    3. ›
  3. D37-D48 Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
    4. ›
  4. D47- Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
    5. ›
  5. 2021 ICD-10-CM Diagnosis Code D47.3

2021 ICD-10-CM Diagnosis Code D47.3

Essential (hemorrhagic) thrombocythemia

    2016 2017 2018 2019 2020 2021 Billable/Specific Code
  • D47.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2021 edition of ICD-10-CM D47.3 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of D47.3 - other international versions of ICD-10 D47.3 may differ.
Applicable To
  • Essential thrombocytosis
  • Idiopathic hemorrhagic thrombocythemia
The following code(s) above D47.3 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to D47.3:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • D37-D48
    2021 ICD-10-CM Range D37-D48

    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes

    Note
    • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
    Type 1 Excludes
    • neoplasms of unspecified behavior (D49.-)
    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
Approximate Synonyms
  • Essential thrombocythemia
  • Thrombocytosis
  • Thrombocytosis (high blood platelets)
Clinical Information
  • A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. The cause is unknown. Median survival times of 10-15 years are commonly reported. (who, 2008)
  • A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
  • An increased number of thrombocytes (platelets) in the blood, without a known cause.
  • Clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
ICD-10-CM D47.3 is grouped within Diagnostic Related Group(s) (MS-DRG v38.0):
  • 814 Reticuloendothelial and immunity disorders with mcc
  • 815 Reticuloendothelial and immunity disorders with cc
  • 816 Reticuloendothelial and immunity disorders without cc/mcc

Convert D47.3 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
Code annotations containing back-references to D47.3:
  • Code Also: D47.02
    , I27.29
    ICD-10-CM Diagnosis Code D47.02

    Systemic mastocytosis

      2018 - New Code 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Indolent systemic mastocytosis
    • Isolated bone marrow mastocytosis
    • Smoldering systemic mastocytosis
    • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
    Code Also
    • , if applicable, any associated hematological non-mast cell lineage disease, such as:
    • acute myeloid leukemia (C92.6-, C92.A-)
    • chronic myelomonocytic leukemia (C93.1-)
    • essential thrombocytosis (D47.3)
    • hypereosinophilic syndrome (D72.1)
    • myelodysplastic syndrome (D46.9)
    • myeloproliferative syndrome (D47.1)
    • non-Hodgkin lymphoma (C82-C85)
    • plasma cell myeloma (C90.0-)
    • polycythemia vera (D45)
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • mast cell leukemia (C94.3-)
    ICD-10-CM Diagnosis Code I27.29

    Other secondary pulmonary hypertension

      2018 - New Code 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Group 5 pulmonary hypertension
    • Pulmonary hypertension with unclear multifactorial mechanisms
    • Pulmonary hypertension due to hematologic disorders
    • Pulmonary hypertension due to metabolic disorders
    • Pulmonary hypertension due to other systemic disorders
    Code Also
    • other associated disorders, if known, such as:
    • chronic myeloid leukemia (C92.10-C92.22)
    • essential thrombocythemia (D47.3)
    • Gaucher disease (E75.22)
    • hypertensive chronic kidney disease with end stage renal disease (I12.0, I13.11, I13.2)
    • hyperthyroidism (E05.-)
    • hypothyroidism (E00-E03)
    • polycythemia vera (D45)
    • sarcoidosis (D86.-)
  • Type 1 Excludes: D69
    , D69
    ICD-10-CM Diagnosis Code D69

    Purpura and other hemorrhagic conditions

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • benign hypergammaglobulinemic purpura (D89.0)
    • cryoglobulinemic purpura (D89.1)
    • essential (hemorrhagic) thrombocythemia (D47.3)
    • hemorrhagic thrombocythemia (D47.3)
    • purpura fulminans (D65)
    • thrombotic thrombocytopenic purpura (M31.1)
    • Waldenström hypergammaglobulinemic purpura (D89.0)
    ICD-10-CM Diagnosis Code D69

    Purpura and other hemorrhagic conditions

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • benign hypergammaglobulinemic purpura (D89.0)
    • cryoglobulinemic purpura (D89.1)
    • essential (hemorrhagic) thrombocythemia (D47.3)
    • hemorrhagic thrombocythemia (D47.3)
    • purpura fulminans (D65)
    • thrombotic thrombocytopenic purpura (M31.1)
    • Waldenström hypergammaglobulinemic purpura (D89.0)

Diagnosis Index entries containing back-references to D47.3:

ICD-10-CM Codes Adjacent To D47.3
D46.4 Refractory anemia, unspecified
D46.Z Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified
D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.0 Mast cell neoplasms of uncertain behavior
D47.01 Cutaneous mastocytosis
D47.02 Systemic mastocytosis
D47.09 Other mast cell neoplasms of uncertain behavior
D47.1 Chronic myeloproliferative disease
D47.2 Monoclonal gammopathy
D47.3 Essential (hemorrhagic) thrombocythemia
D47.4 Osteomyelofibrosis
D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.Z1 Post-transplant lymphoproliferative disorder (PTLD)
D47.Z2 Castleman disease
D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D48 Neoplasm of uncertain behavior of other and unspecified sites
D48.0 Neoplasm of uncertain behavior of bone and articular cartilage
D48.1 Neoplasm of uncertain behavior of connective and other soft tissue
D48.2 Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com